Bioequivalence study of two formulations of doxycycline

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 5, 1998, Pages 315-323

  Kitzes Cohen, Ruth ^a   Farin, Dina ^a   Laor, Arie ^a   Piva, Guillermo ^a   Hazan, Klara ^a   Wasserman, Amit ^a   Gozlan, Igal ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

Bioequlvalence; Doxycycline; Healthy volunteers; High performance liquid chromatography

Indexed keywords

DOXYCYCLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

EID: 0031801607     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85071-6     Document Type: Article

References (24)

1. Bennett WM, Aronoff GR, Golper TA. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 3rd ed. Philadelphia, PA: American College of Physicians; 1994.
2. Petrick RJ, Love SJ, Noris E. The bioavailability and gastrointestinal toleration of doxycycline hyclate tablets. Postgrad Med Comm. 1981;20.
3. Cohen RK, Grauer F, Weisenberg E. Bioequivalence of doxycycline tablets and capsules. Isr J Med Sci. 1980;16:545-546.
4. Saano V, Paronen R, Peura P. Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets. Int J Clin Pharmacol Ther Toxicol. 1990;28:471-474.
5. Campistron G, Coulais Y, Calliard C. Pharmacokinetics and bioavailability of doxycycline in humans. Arzneim-Forsch Drug Res. 1986;36:1705-1707.
6. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15:355-366.
7. Saket M, Qaisi A, Abdel Razzak M, et al. A bioequivalence study of two brands of doxycycline capsules. Curr Ther Res. 1993;54:15-22.
8. Antal EJ, Jaffe JM, Poust RI, Colaizzi JL. Bioequivalency of doxycycline products. J Pharm Sci. 1975;64:2015-2018.
9. Hampel B, Lode H, Fenner H, Gikalov I. Doxycycline pellets: A suitable formulation with warranted bioequivalence. Arzneim-Forsch Drug Res. 1980;30:1938-1943.
10. Malmborg AS. Bioavailability of doxycycline monohydrate. Chemotherapy. 1984;30:76-80.
11. Lode H, Deppermann N, Schmidt U. Bioequivalence of an optimized doxycycline preparation. Arzneim-Forsch Drug Res. 1989;39:1162-1165.
12. Balogh A, Rechenbach C, Brix R, et al. Investigation of the bioequivalence of doxycycline in two capsule preparations. Arzneim-Forsch Drug Res. 1991;41:1289-1293.
13. Lanza FL. Esophageal ulceration produced by doxycycline. Curr Ther Res. 1988;44:475-484.
14. Carlborg B, Farmer JC. Esophageal corrosion tests with doxycycline monohydrate tablets. Curr Ther Res. 1983;34:110-116.
15. Shapiro SS, WiLk MB. An analysis of variance test for normality. Biometrika. 1965;52:591-611.
16. Studies on bioavailability and bioequivalence - APV guideline, international views of politics and science with contributions on development, manufacture, marketing, distribution and therapeutic use of drugs. 1987;30:131-136.
17. US Food and Drug Administration, Division of Biopharmaceutics. Bioavailability Protocol Guidelines for ANDA and NDA Submission. Rockville, MD: US Food and Drug Administration; 1977.
18. Hauschke D, Steinijans VW, Diletti EA. Distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990;28:72-78.
19. Conover WJ. Practical Nonparametric Statistics. New York: Wiley; 1971:384-389.
20. SAS Institute, Inc. SAS for Personal Computers Release 6.12. Cary, NC: SAS Institute, Inc; 1996.
21. Steinijans VW, Hauschke D. Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990;28:105-110.
22. Guidance for Statistical Procedures for Bioequivalence Studies Using a Standard Two Treatment Crossover Design. Rockville, MD: US Food and Drug Administration, Office of Generic Drugs; 1992.
23. Shein CC, Lin JP. Recent statistical developments in bioequivalence trials - A review of the FDA guidance. Drug Inf J. 1994;28:51-64.
24. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol. 1991;29:1-8.